Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis

References

• European AIDS Clinical Society (EACS). EACS Guidelines Version 8.0 – October 2015; 2015. http://www.eacsociety.org/files/guidelines_8_0-english_web.pdf. Accessed July 7, 2016.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2016. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed September 21, 2016.
   Google Scholar
• Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. JAMA. 2016;316(2):191–210.10.1001/jama.2016.8900
   PubMed Web of Science ®Google Scholar
• Abgrall S, Ingle SM, May MT, et al. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. AIDS. 2013;27(5):803–813.
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Ewald H, Santini-Oliveira M, et al. Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis. HIV Clin Trials. 2015;16(5):178–189.10.1179/1945577115Y.0000000004
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008;336(7658):1413–1415.10.1136/bmj.a117
   PubMed Web of Science ®Google Scholar
• HIV Drug Therapy in the Americas Congress 13–15 January 2013, São Paulo Brazil. J Int AIDS Soc. 2013;16(1):1–24.
   Google Scholar
• Raghunathan K, Bonavia A, Nathanson BH, et al. Association between initial fluid choice and subsequent in-hospital mortality during the resuscitation of adults with septic shock. Anesthesiology 2015;123(6):1385–1393.10.1097/ALN.0000000000000861
   PubMed Web of Science ®Google Scholar
• 14th European AIDS Conference 16–19 October 2013. Brussels; 2013. http://www.eacs-conference2013.com/fileadmin/templates/eacs/template_FILES/FINAL_EACS13_Final_Program_web.pdf.
   Google Scholar
• 11th International Congress on Drug Therapy in HIV infection 11–15 November 2012, Glasgow UK. J Int AIDS Soc. 2012;15(4):1–176.
   Google Scholar
• XIX International AIDS Conference 22–27 July 2012, Washington, DC, USA. J Int AIDS Soc. 2012;15(3):1–287.
   Google Scholar
• The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. www.cochrane-handbook.org. Accessed March 2011.
   Google Scholar
• Nuesch E, Trelle S, Reichenbach S, et al. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ. 2009;339:b3244.10.1136/bmj.b3244
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA. Investigating patient exclusion bias in meta-analysis. Int J Epidemiol. 2005;34(1):79–87.
   PubMed Web of Science ®Google Scholar
• Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Internal Med. 1997;127(9):820–826.10.7326/0003-4819-127-9-199711010-00008
   PubMed Web of Science ®Google Scholar
• Loutfy MR, Ackad N, Antoniou T, et al. Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen. HIV Clin Trials. 2007;8(5):259–268.10.1310/hct0805-259
   PubMed Web of Science ®Google Scholar
• Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI-regimens: the HIV STAR study. Antivir Ther. 2012;17(7):1351–1361.10.3851/IMP2443
   PubMed Web of Science ®Google Scholar
• Wohl DA, Bhatti L, Small CB, et al. Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in assure, a randomized, open label, non-inferiority trial. PLoS ONE. 2014;9(5):e96187.10.1371/journal.pone.0096187
   PubMed Web of Science ®Google Scholar
• Negredo E, Domingo P, Perez-Alvarez N, et al. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). J Antimicrob Chemother. 2014;69(12):3368–3371.10.1093/jac/dku300
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Mondi A, Colafigli M, et al. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scand J Infect Dis. 2014;46(1):34–45.10.3109/00365548.2013.840920
   PubMed Web of Science ®Google Scholar
• Nishijima T, Gatanaga H, Shimbo T, et al. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PLoS ONE. 2013;8(8):e73639.10.1371/journal.pone.0073639
   PubMed Web of Science ®Google Scholar
• Haskelberg H, Hoy JF, Amin J, et al. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE. 2012;7(6):e38377.10.1371/journal.pone.0038377
   PubMed Web of Science ®Google Scholar
• Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir‐emtricitabine or abacavir‐lamivudine: a randomized, 96‐week trial. Clin Infect Dis. 2009;49(10):1591–1601.10.1086/599193
   PubMed Web of Science ®Google Scholar
• Curran A, Martinez E, Podzamczer D, et al. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial. Antiviral Ther. 2012;17(4):711–718.10.3851/IMP2081
   PubMed Web of Science ®Google Scholar
• Martinez E, Arranz JA, Podzamczer D, et al. Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/ emtricitabine (TDF/FTC): 3-year results of the BICOMBO study. Paper presented at Conference: 10th International Congress on Drug Therapy in HIV Infection Glasgow United Kingdom. Var.Pagings. 2010.
   Google Scholar
• Martínez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/ emtricitabine in HIV-1-infected patients with virological suppression. JAIDS. 2009;51(3):290–297.10.1097/QAI.0b013e3181aa12d5
   Web of Science ®Google Scholar
• Saumoy M, Ordoñez-Llanos J, Martínez E, et al. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antiviral Ther. 2011;16(4):459–468.10.3851/IMP1785
   PubMed Web of Science ®Google Scholar
• Cohen C, Green J, Olivet H, et al. A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted atazanavir (ATV/r) vs. raltegravir (RAL BID) + ATV/r vs. RAL BID + ATV BID. J Int AIDS Soc. 2012;15(4):18279.
   Google Scholar
• Martínez E, Larrousse M, Podzamczer D, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS. 2010;24(3):F1–F9.10.1097/QAD.0b013e32833562c5
   PubMed Web of Science ®Google Scholar
• Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16(9):1257–1263.10.1097/00002030-200206140-00008
   PubMed Web of Science ®Google Scholar
• Milinkovic A, Martinez E, López S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antiviral Ther. 2007;12:407–415.
   PubMed Web of Science ®Google Scholar
• Koulla-Shiro S, Le Moing V, Ndour C, et al. Randomized comparison of three second line art regimens in Africa: the 2 lady/ANRS/EDCTP study. Paper presented at: Conference on Retroviruses and Opportunistic Infections (abstract and poster 541LB). 2014.
   Google Scholar
• Cooper V, Moyle GJ, Fisher M, et al. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz. AIDS Care. 2011;23(6):705–713.10.1080/09540121.2010.534433
   PubMed Web of Science ®Google Scholar
• Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. JAIDS. 2009;51(5):562–568.10.1097/QAI.0b013e3181ae2eb9
   Web of Science ®Google Scholar
• Campo R, DeJesus E, Bredeek UF, et al. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis. 2013;56(11):1637–1645.10.1093/cid/cis1203
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Orkin C, Fisher M, et al. A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals. PLOS ONE. 2015;10(2):e0116297.10.1371/journal.pone.0116297
   PubMed Web of Science ®Google Scholar
• Orkin C, Moyle G, Fisher M, Wang H, Ewan J, ROCKET I Study Group. Switching from Kivexa [KVX] ABC/3TC + Efavirenz [EFV] to Atripla [ATR] (EFV/FTC/TDF) reduces cholesterol in hypercholesterolemic subjects: preliminary results of a 24-week randomized study. Paper presented at: 16th Annual Conference of the British HIV Association; Apr 21–23, 2010.
   Google Scholar
• Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17(6):1011–1020.10.3851/IMP2305
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, et al. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care and STDs. 2009;23(9):691–697.10.1089/apc.2009.0039
   PubMed Web of Science ®Google Scholar
• Valantin MA, Bittar R, De Truchis P, et al. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate+ emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob Chemother. 2010;65(3):556–561.10.1093/jac/dkp462
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20(16):2043–2050.10.1097/01.aids.0000247574.33998.03
   PubMed Web of Science ®Google Scholar
• McComsey GA, O’Riordan M, Choi J, et al. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir. Antivir Ther. 2012;17(2):347–353.
   PubMed Web of Science ®Google Scholar
• Cotter AG, Vrouenraets SM, Brady JJ, et al. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the prepare study. J Clin Endocrinol Metab. 2013;98(4):1659–1666.10.1210/jc.2012-3686
   PubMed Web of Science ®Google Scholar
• Vrouenraets SM, Fux CA, Wit FW, et al. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS. 2011;25(17):2149–2155.10.1097/QAD.0b013e32834bba87
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalama CM, Ribaudo HJ, et al. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007;21(7):813–823.10.1097/QAD.0b013e32805e8753
   PubMed Web of Science ®Google Scholar
• Ribera E, Larrousse M, Curran A, et al. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study. HIV Med. 2013;14(6):327–336.10.1111/hiv.2013.14.issue-6
   PubMed Web of Science ®Google Scholar
• Rasmussen TA, Tolstrup M, Melchjorsen J, et al. Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis. 2011;11(1):267.10.1186/1471-2334-11-267
   PubMed Web of Science ®Google Scholar
• Rasmussen TA, Jensen D, Tolstrup M, et al. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS ONE. 2012;7(3):e32445.10.1371/journal.pone.0032445
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA, Karassa FB. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. BMJ. 2010;341:c4875.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Internal Med. 2004;141(10):781–788.10.7326/0003-4819-141-10-200411160-00009
   PubMed Web of Science ®Google Scholar
• Hill A, Sawyer W, Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials. 2009;10(1):1–12.10.1310/hct1001-1
   PubMed Web of Science ®Google Scholar
• Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet. 2014;383(9913):267–276.10.1016/S0140-6736(13)62228-X
   PubMed Web of Science ®Google Scholar